Clinical Trial

Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will offer men with intermediate risk prostate cancer who are suitable for, and interested in, prostate brachytherapy, the opportunity to be randomized between low dose rate (LDR) brachytherapy using permanent implantation of radioactive seeds (the current standard of care in BC) and high dose rate (HDR) or temporary brachytherapy which is also available as a standard of care in BC but only when used as a boost in addition with external beam radiotherapy. In addition, men will be offered the opportunity for testing the aggressiveness of their cancer using Cell Cycle Progression Gene Profile.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2016-02-24; most recent amendment 2026-06-24.
Status change: Recruiting → Active, Not Recruiting 2023-05-19
Status change: Not Yet Recruiting → Recruiting 2016-05-31
Trial Details
NCT Number NCT02692105
Lead Sponsor British Columbia Cancer Agency
Conditions Prostate Cancer
Enrollment 60 participants
Start Date 2016-05
Primary Completion 2021-04 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-29